---
layout: default
title: Sodium Chloride
parent: Model Prediction Only (L5)
nav_order: 680
evidence_level: L5
indication_count: 10
---

# Sodium Chloride
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sodium Chloride: From Fluid and Electrolyte Replacement to Breast Fibrocystic Disease

## One-Sentence Summary

Sodium chloride is an electrolyte and fluid replacement agent, and in Australia it is registered as an irrigation solution. The TxGNN model predicts it may be effective for **breast fibrocystic disease**, but **no clinical trials and no supporting publications** have been found for this prediction. It is a graph-based computational prediction only.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the data compiled for this report (the ARTG entries carry no approved indication text) |
| Predicted New Indication | Breast fibrocystic disease |
| TxGNN Prediction Score | 96.79% |
| Evidence Level | L5 (model prediction only) |
| Australia Market Status | Marketed |
| Number of ARTG Entries | 2 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available. Based on known information, sodium chloride is a basic electrolyte and fluid replacement agent, used in solutions for hydration, irrigation and as a vehicle. It has no recognised action on the pathology of fibrocystic breast change, which is generally related to hormonal influences on breast tissue.

The high score appears to reflect proximity in the knowledge graph rather than biological evidence. Several of the other top-ranked predictions are closely related breast conditions (blunt duct adenosis, apocrine adenosis, benign mammary dysplasia) and share near-identical scores. This suggests the predictions are correlated and not independent signals. Other predicted indications are mostly gynaecological (vulvovaginitis, vulvitis, atrophic vaginitis, vulvar ulceration), where saline may play only a supportive role, such as irrigation or cleansing. That is standard care, not a repurposed disease-specific therapy.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available for the lead prediction (breast fibrocystic disease).

For the second-ranked prediction (vulvovaginitis), one publication was retrieved, but it is not supportive evidence:

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [33860751](https://pubmed.ncbi.nlm.nih.gov/33860751/) | 2021 | Case report | Int J Clin Pharmacol Ther | Describes an adverse reaction (chills, fatigue, chest distress, raised white cell count and inflammatory markers) after a terconazole vaginal suppository. It concerns terconazole, not sodium chloride, and shows no therapeutic benefit. |

## Australia Market Information

| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| ARTG 4460R | Baxter Healthcare Pty Ltd | Irrigation solution 9 mg per mL (0.9%), 500 mL | Not stated |
| ARTG 456B | Not stated | Not stated | Not stated |

## Safety Considerations

- **Drug Interactions** (both Moderate severity):
  - Tolvaptan
  - Lithium carbonate

For other warnings and contraindications, please refer to the TGA-approved Product Information (PI) for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by a graph-based model score. There are no clinical trials or relevant publications, and no plausible mechanism links sodium chloride to fibrocystic breast disease. The ARTG entries also carry no approved indication text.

**To proceed, the following is needed:**
- Mechanism of action data and a plausible biological rationale for the breast indication
- A systematic literature search for saline use in benign breast conditions
- Confirmation of the approved indications and formulations from the TGA-approved Product Information
- Assessment of route compatibility, as the registered product is an irrigation solution
- Warnings and contraindications from the Product Information to allow safety screening
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

